Psychiatry Research
Volume 112, Issue 2 , Pages 145-152 , 10 October 2002

A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes

Received 12 December 2001 ,Revised 17 June 2002 ,Accepted 23 July 2002.

References 

  1. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. American Journal of Psychiatry. 1983;140:11–20
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994;
  3. Ballús C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. International Clinical Psychopharmacology. 2000;15:43–48
  4. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European Neuropsychopharmacology. 1997;7(Suppl. 1):S57–S70
  5. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999;39:25–32
  6. Brunello N, Akiskal H, Boyer P, Gessa GL, Howland RH, Langer SZ, et al. Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. Journal of Affective Disorders. 1999;52:275–290
  7. De Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychological Medicine. 1999;29:1273–1289
  8. Dunner DL. Efficacy of selective serotonin re-uptake inhibitors in the treatment of dysthymia. In:  Feighner JP,  Boyer WF editor. Selective Serotonin Re-uptake Inhibitors: Advances in Basic Research and Clinical Practice, 2nd ed. New York: Wiley; 1996;p. 223–232
  9. Dunner DL. Acute and maintenance treatment of chronic depression. Journal of Clinical Psychiatry. 2001;62(Suppl. 6):S10–S16
  10. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. Journal of Clinical Psychiatry. 1997;58:528–531
  11. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Archives of General Psychiatry. 1989;46:971–982
  12. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Disorders (SCID). Washington, DC: American Psychiatric Press; 1997;
  13. Fredman L, Weissman MM, Leaf PJ, Bruce ML. Social functioning in community residents with depression and other psychiatric disorders: results of the New Haven Epidemiologic Catchment Area Study. Journal of Affective Disorders. 1988;15:103–112
  14. Friedman RA, Markowitz JC, Parides M, Gniwesch L, Kocsis JH. Six months of desipramine for dysthymia: can dysthymic patients achieve normal social functioning?. Journal of Affective Disorders. 1999;54:283–286
  15. Gessa GL. Dysthymia and depressive disorders: dopamine hypothesis. European Psychiatry. 1996;11(Suppl. 3):S123–S127
  16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration; 1976;
  17. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  18. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. American Journal of Psychiatry. 1993;150:1169–1175
  19. Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, et al. Double blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. American Journal of Psychiatry. 1997;154:390–395
  20. Lam DH, Green B, Power MJ, Checkley S. The impact of social cognitive variables on the initial level of depression and recovery. Journal of Affective Disorders. 1994;32:75–83
  21. Leader JB, Klein DN. Social adjustment in dysthymia, double depression and episodic major depression. Journal of Affective Disorders. 1996;37:91–101
  22. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. Journal of Affective Disorders. 1997;43:95–103
  23. Lonnqvist J, Sintonen H, Syvalathi E, Appelberg B, Koskinen T, Mannikko T, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatrica Scandinavica. 1994;89:363–369
  24. McLeod MN, Gaynes BN, Golden RN. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. Journal of Clinical Psychiatry. 1999;60:237–240
  25. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 1979;134:382–389
  26. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics. 1997;280:73–82
  27. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Journal of Clinical Psychiatry. 2000;61:821–827
  28. Ravizza L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. Journal of Psychopharmacology. 1999;13:248–254
  29. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics. 1997;280:83–97
  30. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. Journal of Affective Disorders. 1998;48:47–56
  31. Souêtre E, Martin P, Lozet H, Monteban H. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. International Clinical Psychopharmacology. 1996;11:45–52
  32. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Archives of General Psychiatry. 1996;53:777–784
  33. Turner R. Quality of life: experience with sertraline. International Clinical Psychopharmacology. 1994;9(Suppl. 3):S27–S31
  34. Vanelle JM, Attar-Levy D, Poirier MF, Bouhassira M, Blin P, Oliè JP. Controlled efficacy study of fluoxetine in dysthymia. British Journal of Psychiatry. 1997;170:345–350
  35. Versiani M. Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. Journal of Affective Disorders. 1998;51:323–332
  36. Weissman MM, Leaf PJ, Bruce ML, Florio L. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. American Journal of Psychiatry. 1988;145:815–819
  37. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. Journal of the American Medical Association. 1989;262:914–919
  38. WPA Dysthymia Working Group . Dysthymia in clinical practice. British Journal of Psychiatry. 1995;166:174–183

PII: S0165-1781(02)00188-9

Psychiatry Research
Volume 112, Issue 2 , Pages 145-152 , 10 October 2002

Article Tools